Angiopoietin-2和α5β1 Integrin在乳腺癌中表达及其临床病理意义  

Expression and Clinicopathological Significance of Angiopoietin-2 and α5β1 Integrin in the Breast Cancer

作　　者：李晶[1,2,3] 欧阳取长 肖华伍[1,2] 邓亚平 曾亮[1,4,5] 

机构地区：[1]湖南省肿瘤医院 [2]中南大学湘雅医学院附属肿瘤医院乳腺内科,湖南长沙410013 [3]吐鲁番地区中心医院内一科,新疆吐鲁番838000 [4]中南大学湘雅医学院附属肿瘤医院病理科,湖南长沙410013 [5]吐鲁番地区中心医院病理科,新疆吐鲁番838000

出　　处：《现代生物医学进展》2013年第21期4128-4131,共4页Progress in Modern Biomedicine

基　　金：湖南省科学技术厅科技计划(2010FJ3154)

摘　　要：目的:探讨Angiopoietin-2和α5β1 Integrin在乳腺癌中表达及其临床病理学意义。方法:选择2005年1月至2011年12月湖南省肿瘤医院收治的180例乳腺癌病例和80例乳腺良性病变者为研究对象,应用免疫组织化学技术检测乳腺癌组织和乳腺良性病变者正常乳腺组织中Angiopoietin-2和α5β1 Integrin的表达,并分析其与患者的生存期及淋巴结转移的相关性。结果:Angiopoietin-2在乳腺癌和正常乳腺组织中的阳性表达率分别为80.56%(145/180)和11.25%(9/80),α5β1 Integrin在乳腺癌和正常乳腺组织中的阳性表达率分别为77.22%(139/180)和16.25%(13/80),乳腺癌中Angiopoietin-2和α5β1 Integrin的阳性表达率均显著高于在正常乳腺组织中的表达(P<0.05),但乳腺癌组织中Angiopoietin-2和α5β1 Integrin的表达无显著相关性(P>0.05)。有淋巴结转移及无淋巴结转移的乳腺癌中Angiopoietin-2的阳性表达率分别为97.93%(95/97)和60.03%(50/83),差异有统计学意义(P<0.05);而有淋巴结转移及无淋巴结转移的乳腺癌中α5β1 Integrin的阳性表达率分别83.5%(81/97)和69.87%(58/83),差异无统计学意义(P>0.05)。Angiopoietin-2和/或α5β1 Integrin阴性表达的乳腺癌患者生存期分别显著高于Angiopoietin-2和/或α5β1 Integrin阳性的乳腺癌患者(P<0.01),差异有统计学意义(P<0.01)。结论:Angiopoietin-2和α5β1 Integrin的表达上调可能在乳腺癌的发生发展过程中起重要作用,并可能作为预测乳腺癌患者预后的参考指标。Objective： To investigate the expression and clinicopathological significance of angiopoietin-2 and α5β1 integrin in the breast cancer.Methods： 180 cases of breast cancer and 80 cases of benign breast lesion admitted in Hunan Tumor Hospital from January 2005 to December 2011 were selected,the immunohistochemical method was applied to detect the Angiopoietin-2 and α5β1 Integrin expression,and relation of their expressions to survival and lymph node metastasis was analyzed.Results： The positive rates of Angiopoietin-2 expression in breast cancer and normal breast tissue were respectively 80.56%（145/180） and 11.25%（9/80）,the positive rates of α5β1 Integrin expression in breast cancer and normal breast tissue were respectively 77.22%（139/180） and 16.25%（13/80）,which were significantly higher in the breast cancer than those in the normal breast tissue（P0.01）,but no significant correlationwas found between the expressions of Angiopoietin-2 andα5β1 Integrin in.The breast cancer（P0.05）.The positive rate of Angiopoietin-2 expression was 97.93%（95/97） in breast cancer with lymph node metastasis and 60.03%（50/83）in breast cancer without lymph node metastasis,which was significantly higher in the breast cancer with lymph node metastasis than that in the breast cancer without lymph node metastasis（P0.05）.However,the positive rate of α5β1 Integrin was 83.5%（81/97） in the breast cancer with lymph node metastasis and 69.87%（58/83） in the breast cancer without lymph node metastasis,no,marked difference was found between them（P0.05）.The survival time of Angiopoietin-2-negative and/or α5β1 Integrin-negative breast cancer were longer than Angiopoietin-2-positive and/or α5β1 Integrinpositive breast cancer（P0.01）.Conclusion： The up-regulation of Angiopoietin-2 and α5β1 Integrin expressions may play an important role in the development of breast cancer and could be used as prognostic indicators for the evaluation of prognosis of patients with breast cancer.

关 键 词：血管生成素 整合素 乳腺癌 预后 

分 类 号：R602[医药卫生—外科学] R737.9[医药卫生—临床医学]